PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.\', \'Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.\', \'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.\', \'Department of Medicine, Harvard Medical School, Boston, MA, USA.\', \'Department of Cancer Cell Biology, Dana-Farber Cancer Institute, Boston, MA, USA.\', \'Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.\', \'Department of Surgery, Brigham and Women\'s Hospital, Boston, MA, USA.\', \'High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, Anhui, China.\', \'Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.\', \'Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s11095-020-02851-7
?:doi
?:hasPublicationType
?:journal
  • Pharmaceutical research
is ?:pmid of
?:pmid
?:pmid
  • 32778962
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.077
?:rankingScore_hIndex
  • 182
is ?:relation_isRelatedTo_publication of
?:title
  • Repurposing of Kinase Inhibitors for Treatment of COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32778962>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32778962>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all